Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA Delivery and Immune Stimulation for Melanoma Gene Therapy
- 11 December 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (1) , 267-282
Abstract
Messenger ribonucleic acid (mRNA)-based gene therapy has great potential for cancer gene therapy. However, the effectiveness of mRNA in cancer therapy needs to be further improved, and the delivery efficiency and instability of mRNA limit the application of mRNA-based products. Both the delivery efficiency can be elevated by cell-penetrating peptide modification, and the immune response can be enhanced by tumor cell lysate stimulation, representing an advantageous strategy to expand the effectiveness of mRNA gene therapy. Therefore, it is vital to exploit a vector that can deliver high-efficiency mRNA with codelivery of tumor cell lysate to induce specific immune responses. We previously reported that DMP cationic nanoparticles, formed by the self-assembly of DOTAP and mPEG-PCL, can deliver different types of nucleic acids. DMP has been successfully applied in gene therapy research for various tumor types. Here, we encapsulated tumor cell lysates with DMP nanoparticles and then modified them with a fused cell-penetrating peptide (TAT-iRGD) to form an MLSV system. The MLSV system was loaded with encoded Bim mRNA, forming the MLSV/Bim complex. The average size of the synthesized MLSV was 191.4 nm, with a potential of 47.8 mV. The MLSV/mRNA complex promotes mRNA absorption through caveolin-mediated endocytosis, with a transfection rate of up to 68.6% in B16 cells. The MLSV system could also induce the maturation and activation of dendritic cells, obviously promoting the expression of CD80, CD86, and MHC-II both in vitro and in vivo. By loading the encoding Bim mRNA, the MLSV/Bim complex can inhibit cell proliferation and tumor growth, with inhibition rates of up to 87.3% in vitro. Similarly, the MLSV/Bim complex can inhibit tumor growth in vivo, with inhibition rates of up to 78.7% in the B16 subcutaneous tumor model and 63.3% in the B16 pulmonary metastatic tumor model. Our results suggest that the MLSV system is an advanced candidate for mRNA-based immunogene therapy.Keywords
Funding Information
- University of Electronic Science and Technology of China (ZYGX2021YGLH225)
- Science and Technology Department of Sichuan Province (23NSFJQ0104, 2023YFS0165)
- Science Foundation of Chengdu (2022-YF05-01793-SN)
This publication has 54 references indexed in Scilit:
- Plasmacytoid dendritic cell in immunity and cancerJournal of Neuroimmunology, 2018
- Cancer immunotherapy: broadening the scope of targetable tumoursOpen Biology, 2018
- Poly(β‐amino ester)‐co‐poly(caprolactone) Terpolymers as Nonviral Vectors for mRNA Delivery In Vitro and In VivoAdvanced Healthcare Materials, 2018
- Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and TumorsCell Metabolism, 2017
- Fluorophore−Quencher Based Activatable Targeted Optical Probes for Detecting in Vivo Cancer MetastasesMolecular Pharmaceutics, 2009
- Mechanisms and Consequences of Dendritic Cell MigrationImmunity, 2008
- TAT-mediated Delivery of LAD Restores Pyruvate Dehydrogenase Complex Activity in the Mitochondria of Patients with LAD DeficiencyMolecular Therapy, 2008
- Macrophage C-type lectin on bone marrow-derived immature dendritic cells is involved in the internalization of glycosylated antigensGlycobiology, 2002
- Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunityGene Therapy, 1999
- Effect of different sex of tumour bearing mice and of ovariectomy on the proliferation kinetics of a solid, transplantable mammary carcinoma (C3H-mouse)Journal of Cancer Research and Clinical Oncology, 1976